Biomedical Technology

GoldPorp Pharma Limited

🚫 No Website Found 🏢 HKSTP Source
52 Potential

Decision Maker

Professor Chi Ming CHE
goldporp1@outlook.com
39103982
Room 03, 1/F, 9W and S20 & S21, 6/F, Building 17W, No. 9 and 17 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, N.T.
Raw Description
Product | Anti-cancer gold compounds have been actively studied in the pursuit of new metal-based anticancer therapeutics due to their much higher in vitro and in vivo cytotoxicity and anti-proliferative activities compared to the current platinum chemotherapy used clinically. Prof. Chi-Ming CHE’s research team at the University of Hong Kong has discovered and developed novel gold compounds displaying promising anti-tumor activity towards a broad spectrum of metastatic cancers. These proprietary gold compounds against multiple protein targets provide much better efficacy than cisplatin and carboplatin used for the treatment of advanced metastatic cancer: | • Proven to be effective against various a broad spectrum of cancers in multiple animal models, including the orthotropic ones | • Superior to the clinically used chemotherapy in cancer patient-derived organoids | • Effective against tumors such as nasopharyngeal carcinoma, liver cancer and pancreatic cancers that have no effective chemotherapy | • Effective toward drug-resistant cancer | • Inhibit metastasis and angiogenesis | • Eliminate cancer stem cells | • Binding to multiple oncogenic molecular targets that are responsible for the proliferation, invasion and migration of cancer cells with high affinity at sub-micro-molar concentrations. | Prof. Che’s team has developed new proprietary anti-cancer platinum compounds with similar efficacy to cisplatin but comparable safety profile as carboplatin. The direct molecular targets of these new anti-cancer platinum compounds have been identified and will be developed to replace cisplatin or carboplatin in the treatment of Stage IV Metastatic Cancers, either as a therapy alone or in combination with immunotherapy. || GoldPorp is dedicated to the discovery, development and commercialization of best-in-class Targeted Chemotherapy for the treatment of advanced metastatic cancer. Our discovery and development efforts are focused on (1) drug candidates showing strong binding affinity to pivotal oncogenic proteins that are responsible for tumorigenesis migration and invasion of cancer cells, (2) formulation of these drug candidates to maintain their in vivo efficacy but with minimal toxicity, and (3) combined treatment based on our targeted chemotherapy and immunotherapy. GoldPorp aims to develop Superior Anti-Cancer Metal Medicines that are best-in-class in safety and efficacy, effectively turning late-stage cancers into a curable chronic disease. | Professor Che and the team have developed proprietary anti-cancer metal compounds that show excellent efficacy in killing metastasized cancer cells at animal-tolerable dosages in the studies. These inventions have been and will be exclusively licensed to GoldPorp, and we will further optimize the structures and develop formulations of these proprietary anti-cancer compounds, develop synergized combination therapies for cancer treatment, and antibody drug conjugates of these proprietary anti-cancer metal compounds. | Description | GoldPorp is dedicated to the discovery, development and commercialization of best-in-class Targeted Chemotherapy for the treatment of advanced metastatic cancer.

Strategic Analysis

Executive Brief

GoldPorp Pharma Limited is a biotechnology firm specializing in the development of next-generation metal-based anti-cancer therapeutics, specifically targeting metastatic and drug-resistant cancers. Leveraging research from the University of Hong Kong, they focus on gold and platinum-based compounds that exhibit high cytotoxicity toward tumors while maintaining lower toxicity profiles than traditional cisplatin treatments. Their work involves complex molecular targeting, antibody-drug conjugates (ADCs), and precision formulation of organometallic compounds.

Strategic Fit & Lead Score

Lead Score: 52 (40-59: General Research / Engineering)

Why this Score? While GoldPorp is a pharmaceutical entity and not a traditional materials player, their core technology relies on the electrochemistry and stability of precious metal compounds. 6C's Boron-Doped Diamond (BDD) technology provides the world's most stable electrochemical interface, which is critical for the analytical detection and characterization of gold-based drugs in complex biological fluids. Furthermore, diamond’s extreme bio-compatibility makes it a candidate for high-end in-vitro diagnostic (IVD) hardware used during their drug development and clinical monitoring phases.

6C Solutions Proposal

Application Area 6C Solution Technical Value Prop
Pharmacokinetics (PK) Analysis BDD Electrochemical Electrodes BDD has the widest electrochemical window and lowest background current. It allows for the ultra-sensitive detection of gold(III) and platinum(II) compounds in blood/serum without the surface fouling (passivation) common in gold or carbon electrodes.
Drug Delivery Systems Fluorescent Nanodiamonds (SCD-based) 6C can provide ultra-pure SCD for the creation of functionalized nanodiamond carriers. Diamond is non-toxic and can be conjugated with GoldPorp’s gold-complexes to track drug delivery in-vivo via NV-center fluorescence.
Microfluidic Diagnostics Diamond-on-Sensing Chips Direct MPCVD coating of diamond on sensor substrates for organ-on-a-chip or patient-derived organoid testing. Diamond's surface is chemically inert, preventing the drug compounds from "sticking" to the test equipment, ensuring accurate efficacy data.
Bio-Sensing Research Custom MPCVD Reactors If GoldPorp seeks to develop proprietary diagnostic hardware for their metal-medicines, 6C can provide a custom MPCVD system to grow tailored diamond films for their specific biosensor patents.

Engagement Hooks

  • Technical Question: "How are you currently addressing electrode fouling and signal interference when performing electrochemical characterization of your gold-based compounds in protein-heavy environments like patient-derived organoids?"
  • Value Statement: "6C's Boron-Doped Diamond (BDD) technology offers an unmatched electrochemical window, enabling GoldPorp to achieve sub-micromolar detection sensitivity for your proprietary metal therapeutics in complex biological matrices."